Royalty Pharma Plc Cash Flow Conversion Efficiency
Royalty Pharma Plc cash flow conversion efficiency. Based on the latest financial reports, Royalty Pharma Plc (RPRX) has a cash flow conversion efficiency ratio of 0.077x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($760.54 Million) by net assets ($9.94 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Royalty Pharma Plc (2002–2025)
Cash flow conversion efficiency of Royalty Pharma Plc from 2002 to 2025. This chart illustrates how Royalty Pharma Plc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Royalty Pharma Plc stock quote for real-time trading data and today's change.
Royalty Pharma Plc Cash Flow Conversion Ratio Explained
Royalty Pharma Plc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Royalty Pharma Plc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Royalty Pharma Plc ranked by their cash flow conversion efficiency. Also see RPRX market cap overview for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
FANUC CORP.UNSP.ADR 1/10
F:FUCA
|
N/A |
|
Credicorp Ltd
MX:BAPN
|
-0.020x |
|
Bharat Electronics Limited
NSE:BEL_old
|
0.013x |
|
China National Nuclear Power
SHG:601985
|
0.057x |
|
Givaudan SA
SW:GIVN
|
0.035x |
|
Jentech Precision Industrial Co Ltd
TW:3653
|
0.065x |
|
Fresenius SE & Co. KGaA
XETRA:FRE
|
0.039x |
|
HOCHTIEF Aktiengesellschaft
F:HOT
|
0.694x |
Annual Cash Flow Conversion Efficiency for Royalty Pharma Plc (2002–2025)
The table below shows the annual cash flow conversion efficiency of Royalty Pharma Plc from 2002 to 2025. Review Royalty Pharma Plc free cash flow ratio to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $9.71 Billion | $2.49 Billion | 0.256x | -4.27% |
| 2024-12-31 | $10.34 Billion | $2.77 Billion | 0.268x | -9.64% |
| 2023-12-31 | $10.08 Billion | $2.99 Billion | 0.296x | +31.63% |
| 2022-12-31 | $9.53 Billion | $2.14 Billion | 0.225x | +14.34% |
| 2021-12-31 | $10.25 Billion | $2.02 Billion | 0.197x | +44.87% |
| 2020-12-31 | $14.97 Billion | $2.03 Billion | 0.136x | -49.94% |
| 2019-12-31 | $6.14 Billion | $1.67 Billion | 0.271x | -23.64% |
| 2018-12-31 | $4.55 Billion | $1.62 Billion | 0.356x | +12.03% |
| 2017-12-31 | $4.47 Billion | $1.42 Billion | 0.317x | +9183.95% |
| 2016-12-31 | $4.46 Billion | $-15.58 Million | -0.003x | +35.22% |
| 2015-12-31 | $4.70 Billion | $-25.33 Million | -0.005x | +99.19% |
| 2014-12-31 | $44.02 Million | $-29.33 Million | -0.666x | -240.37% |
| 2003-12-31 | $23.49 Million | $11.15 Million | 0.475x | +50.95% |
| 2002-12-31 | $26.85 Million | $8.45 Million | 0.315x | -- |
About Royalty Pharma Plc
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabe… Read more